The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.

This new visiongain report describes India’s domestic as well as export market for pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly expanding market with a population of over a billion and a rapidly expanding economy. Prevalence values of many diseases are likely to increase with expansion of population, urbanisation and with higher identification rates in the coming decade. India's pharmaceutical market is increasingly important in global pharma, with both domestic and foreign companies benefiting. Healthcare provision – both public and private – is improving, leading to fast-expanding markets for healthcare products, especially modern pharmaceuticals, visiongain concludes.

Outsourcing for Contract Research and Manufacturing Services from India

The report also analyses India’s role in pharma outsourcing services. India is emerging as a competitive outsourcing hub and is playing a major role in the global pharmaceutical industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical companies are establishing long-term relationships with Indian manufacturing companies and contract research providers in India.

Generic drugs produced in India are increasingly being accepted worldwide, with leading companies such as Ranbaxy, Cipla and Dr. Reddy’s paving the way for others. Indian companies have increasingly taken on outsourced manufacturing for foreign clients, in addition to marketing pharmaceuticals themselves. There are also new drug development programmes by Indian companies, with eventual international market launches. Outsourcing to India has proven to be effective in saving costs and valuable developmental time. The Indian pharmaceutical industry has taken an important role in global pharma, not only as a manufacturer of generic drugs and APIs but also of new formulations.

Increasing costs for research and development and low productivity have compelled major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to lower-cost, developing nations such as India and China. India's emphasis on research and development and new drug discovery is growing. Furthermore, India is emerging as the preferred destination for outsourcing clinical trials, with both high quality and lower costs achieved there.

• With the introduction of ‘product patent regime’ in 2005, India is expected to receive further investment from international pharmaceutical companies in the years ahead

• Global pharmaceutical companies are establishing long-term relationships with Indian pharmaceutical companies and the contract manufacturing affiliates in India, in addition to establishing manufacturing, R&D and marketing bases there

Why You Should Buy This Report

In this report you will receive the following essential information for understanding the Indian pharma market and industry:

• The value of the Indian pharmaceutical market and its principal market segments from 2008 to 2023

• Exports values of the Indian pharmaceutical sector present and future

• Which current or future therapies that will drive the market for India’s pharmaceutical industry from 2008 to 2023

• Market drivers and restraints, including a comprehensive SWOT analysis

• Comprehensive views of key opinion leaders on Indian pharma

• The companies involved in the market and their business strategy

• What are the forecasts for sales for each of the therapeutic areas

• What is the present state of disease prevalence and future trends there

• What contract research and manufacturing opportunities exist for ‘new comers’

This Report is essential reading for the Following Professionals, Amongst Others:

• Investors in the India’s pharmaceutical industry

• Business managers of multinational companies

• Business managers of India’s domestic companies

• Business managers of pharmaceutical industry related to outsourcing

• Researchers, analysts and academics interested in India’s pharmaceutical industry

• Senior staff in healthcare authorities relevant to India

Great Potential for the Indian Pharma Sector and Market from Present Onwards, Visiongain Concludes

Currently, India's largest selling medicines are anti-infective agents, but the fast growing areas are the lifestyle-related diseases, the foreign multinational companies will benefit from selling innovative treatments for these conditions.

With increasing prevalence of diseases of aging and lifestyle-related diseases associated with greater affluence, India's pharmaceutical market will continue to increase steadily in sales value from 2008 onwards. Furthermore, with rapid increase in drug resistance for anti-infective agents like anti-TB, anti-malarial and other antibiotics, visiongain further emphasises that there will be a particularly strong market for most types of pharmaceutical agents – both new and established - from 2008 to 2023.

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

- PRICING -

- Single use licence $2995.00

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00

May 2008
Table of Contents

Price
Single Use Licence $2995.00
Department Licence 5 Users $5,995.00
Company-wide Intranet Licence $9,995.00
Company over 2500 employees $13,995.00